[1/6] Jan Gilpin poses with a bottle of the asthma and allergy drug Singulair, first prescribed to her son when he was three-years-old, at her home in Newton, Massachusetts, U.S., June 21, 2023.
That team found in 2015 that the drug’s distribution into the brain was more significant than its label described.
Lawsuits filed against Merck cite this 1996 patent as evidence of Merck’s knowledge of the drug’s potential brain impacts.
Marschallinger and her colleagues in Austria came away with a different finding when they reviewed Merck’s original research and did some of their own.
Marschallinger said it would have been logical for the FDA to require Merck to investigate the brain impacts more thoroughly once reports of mental-health problems emerged.
Persons:
Jan Gilpin, Singulair, Brian Snyder, Merck, Julia Marschallinger, Marschallinger, ” Marschallinger, “ It’s, Robin Respaut, Dan Levine, Janet Roberts, Brian Thevenot
Organizations:
REUTERS, Brian Snyder Companies Merck, Co, FDA, Molecular Regenerative, Singulair, Merck, Thomson
Locations:
Newton , Massachusetts, U.S, Austria